hsp-110 Antibody

What is HSP110 and why is it an important research target?

HSP110 belongs to the HSP110/SSE family of large stress proteins, sharing 30-33% amino acid identity with the HSP70 family primarily in the conserved ATP-binding domain. It functions as a molecular chaperone crucial for maintaining protein homeostasis (proteostasis) in eukaryotic cells . HSP110 is constitutively expressed in mammalian cells with highest levels in brain tissue and is strongly induced by heat shock, correlating with cellular thermotolerance . Its roles in protein disaggregation, RNA stability, and as an immunoadjuvant in anti-tumor vaccine development make it a valuable research target . Additionally, HSP110 has been implicated in neurodegenerative diseases involving protein aggregation and as a potential diagnostic biomarker in certain cancers .

What applications are HSP110 antibodies most commonly used for?

HSP110 antibodies are employed across multiple research applications, with varying degrees of validation depending on the specific antibody product:

When selecting an HSP110 antibody, researchers should verify the validation data for their specific application of interest, as not all antibodies perform equally across all techniques .

How should HSP110 antibodies be validated before experimental use?

Proper validation of HSP110 antibodies is critical for experimental reproducibility. A comprehensive validation approach should include:

How can HSP110 antibodies be used to study protein disaggregation mechanisms?

HSP110 functions as a critical nucleotide exchange factor for HSP70 in the protein disaggregation machinery. Advanced research applications utilizing HSP110 antibodies can illuminate these mechanisms:

• Co-immunoprecipitation studies: HSP110 antibodies can be used to pull down HSP110 complexes with HSP70 and other co-chaperones to study the composition of disaggregation machinery in different conditions .

• Proximity ligation assays: These can detect direct interactions between HSP110 and substrate proteins or other chaperones with spatial resolution in cells.

• Disaggregation activity measurement: Researchers can combine HSP110 knockdown with antibody detection to correlate HSP110 levels with disaggregation activity. For example, C. elegans studies showed that HSP-110 knockdown led to persistence of heat-induced amorphous aggregates of FLUCSM::EGFP, suggesting impaired disaggregation activity .

• Amyloid propagation studies: HSP110 antibodies can help track how the HSP70/HSP110 disaggregation system generates spreading-competent protein seeds. Research has shown that this system can either reduce toxic protein aggregation or paradoxically produce more toxic protein species depending on context .

The complex relationship between HSP110 levels and disaggregation outcomes requires careful experimental design - both too low and too high HSP110 levels can impair HSP70-mediated disaggregation by affecting the ATPase cycle .

What are the considerations when using HSP110 antibodies in neurodegenerative disease research?

When studying neurodegenerative diseases characterized by protein aggregation, several key considerations should guide HSP110 antibody use:

• Brain tissue-specific optimization: Since HSP110 is highly expressed in brain tissue, antibody dilutions may need adjustment compared to other tissues .

• Distinguish between aggregate types: HSP110's effects differ between amorphous aggregates and amyloid structures. For example, studies show that HSP-110 knockdown in C. elegans leads to persistence of heat-induced amorphous aggregates but can reduce amyloid aggregation depending on timing and strength of knockdown .

• Co-chaperone interactions: Use co-staining with antibodies against HSP70 family members and other co-chaperones to understand the full chaperone network in disease states.

• Temporal considerations: The timing of HSP110 modulation affects disaggregation outcomes. Early and continuous HSP110 knockdown may have different effects than transient modulation .

• Isoform detection: Human cells express three HSP110 isoforms (HSP105/HSPH1, APG2/HSPH2, and APG1/HSPH3) with potentially different roles in neurodegenerative processes . Antibodies with different specificities may be required to distinguish these isoforms.

How can HSP110 antibodies be used as diagnostic tools in cancer research?

HSP110 has emerging potential as a diagnostic biomarker in cancer research. When using HSP110 antibodies for this purpose:

• Antibody epitope selection: Some antibodies target the C-terminus of wild-type HSP110 and do not recognize truncated HSP110 variants associated with certain cancers. This specificity is critical for diagnostic applications .

• Scoring systems for immunohistochemistry: Implement standardized scoring systems for HSP110 expression:

  • Four-tier intensity scores (0-3) where:

    • 0 = no expression

    • 1-3 = increasing levels of expression compared to internal controls

  • Define "nuclear positivity" as nuclear staining in at least 10% of tumor cells

  • Use the "dominant intensity score" (most represented score in the largest tumor area)

• Internal controls: Employ normal colonic mucosal epithelial cells and/or lymphocytes as positive controls for standardizing staining intensity .

• Blinded assessment: For research validity, HSP110 staining should be independently assessed by multiple expert pathologists unaware of other experimental results .

While HSP110 shows promise as a diagnostic biomarker, research indicates it may not have significant prognostic value in all cancer types, highlighting the importance of careful data interpretation .

What are common issues with HSP110 antibody specificity and how can they be addressed?

Researchers frequently encounter specificity challenges when working with HSP110 antibodies:

• Cross-reactivity with HSP70 family proteins: Due to the 30-33% sequence homology with HSP70 family members, some antibodies may cross-react. Mitigation strategies include:

  • Using antibodies targeting unique regions of HSP110 not present in HSP70

  • Validating specificity with HSP110 knockdown/knockout controls

  • Performing peptide competition assays

• Isoform detection issues: Human cells express multiple HSP110 family members (HSP105/HSPH1, APG2/HSPH2, and APG1/HSPH3) . When isoform-specific detection is needed:

  • Verify the epitope recognized by the antibody

  • Use RT-PCR to correlate protein detection with mRNA expression of specific isoforms

  • Consider using recombinant protein standards of each isoform as controls

• Non-specific background in immunostaining: To reduce background:

  • Optimize blocking conditions (try different blockers: BSA, normal serum, commercial blockers)

  • Test different antibody dilutions (typically starting at 1:1,000 for Western blots)

  • Include appropriate negative controls (secondary antibody alone, isotype controls)

  • Consider tissue-specific autofluorescence quenching for IF applications

How should experimental conditions be optimized when using HSP110 antibodies to study stress responses?

HSP110 is a stress-inducible protein, which requires careful consideration of experimental conditions:

• Baseline expression control: Maintain consistent culture conditions prior to experiments, as variations in temperature, confluence, and serum levels can affect baseline HSP110 expression.

• Stress induction protocols: When studying stress-induced HSP110 upregulation:

  Stress Type	Typical Conditions	HSP110 Detection Timing
  Heat shock	42-43°C for 1-3 hours	6-24 hours post-stress
  Oxidative stress	H₂O₂ (0.1-1 mM)	12-24 hours post-treatment
  ER stress	Tunicamycin (1-5 μg/ml)	12-24 hours post-treatment
  Proteasome inhibition	MG132 (1-10 μM)	12-24 hours post-treatment

• Sample preparation considerations:

  • For Western blot: Include protease inhibitors and phosphatase inhibitors in lysis buffers

  • For immunofluorescence: Optimize fixation method (paraformaldehyde vs. methanol) as this can affect epitope accessibility

  • For immunohistochemistry: Test multiple antigen retrieval methods (heat-induced vs. enzymatic)

• Context-specific controls: When studying HSP110 in stress conditions, include both negative controls (unstressed samples) and positive controls (samples with known HSP induction).

What experimental approaches can resolve contradictory findings regarding HSP110's role in protein aggregation?

Contradictory findings have emerged regarding HSP110's role in protein aggregation. For example, organism-wide knockdown of HSP-110 in C. elegans reduced Q35 aggregation in one study but increased it in another . To address such contradictions:

• Temporal resolution studies: The timing of HSP110 modulation affects outcomes. Design experiments with:

  • Inducible knockdown/overexpression systems to control timing

  • Time-course analysis of protein aggregation following HSP110 modulation

  • Pulse-chase experiments to distinguish effects on formation vs. clearance of aggregates

• Tissue-specific analysis: HSP110 effects may differ between tissues. Use:

  • Tissue-specific promoters for knockdown/overexpression

  • Tissue-specific RNAi approaches (as used in C. elegans with sid-1 mutation to prevent systemic RNAi)

  • Single-cell resolution imaging to detect cell-type specific differences

• Aggregate characterization: Distinguish between different types of aggregates:

  • Amorphous vs. amyloid aggregates (using conformation-specific dyes or antibodies)

  • Soluble vs. insoluble fractions (through differential centrifugation)

  • Toxic vs. non-toxic species (through cell viability assays)

• Functional redundancy assessment: In humans, the redundancy of HSP110-type co-chaperones (HSP105/HSPH1, APG2/HSPH2, and APG1/HSPH3) may complicate analysis . Approaches include:

  • Individual and combinatorial knockdown of all isoforms

  • Rescue experiments with individual isoforms

  • Isoform-specific antibodies to track expression patterns

How can HSP110 antibodies be utilized in studying infectious disease mechanisms?

Recent research has revealed potential applications for HSP110 antibodies in infectious disease research:

• Fungal pathogen studies: The pathogenic fungus Candida albicans possesses a single HSP110 protein called Msi3, which has been identified as a potential target for antifungal development . HSP110 antibodies can be used to:

  • Track Msi3 expression during infection stages

  • Validate target engagement of Msi3 inhibitors like pyrazolo[3,4-b]pyridine derivative (HLQ2H/2H)

  • Investigate protein folding mechanisms in fungal cells

• Host-pathogen interaction analysis:

  • Examine HSP110 induction in host cells during infection

  • Study co-localization of host HSP110 with pathogen components

  • Investigate HSP110's role in immune responses to pathogens

• Drug development applications:

  • Screen for compounds that modulate HSP110 activity using antibody-based assays

  • Validate on-target effects of HSP110-targeting therapeutics

  • Study the correlation between drug efficacy and HSP110 inhibition

The identification of HSP110 inhibitors like 2H that affect both Msi3's chaperone activity and fungal viability demonstrates the potential of HSP110 as a therapeutic target in infectious disease research .

What methodological approaches enable the study of HSP110's role in immunomodulation?

HSP110's potential as an immunoadjuvant in anti-tumor vaccine development necessitates specialized methodological approaches:

• Peptide-binding studies:

  • Use HSP110 antibodies in pull-down assays to identify peptides bound to HSP110

  • Employ proximity ligation assays to detect HSP110-peptide interactions in situ

  • Investigate how peptide binding affects HSP110 conformation and function

• Antigen presentation analysis:

  • Track HSP110-peptide complexes during antigen presentation

  • Study dendritic cell activation following exposure to HSP110-peptide complexes

  • Investigate cross-presentation of HSP110-associated antigens

• T-cell response measurement:

  • Analyze T-cell activation in response to HSP110-associated antigens

  • Study memory T-cell formation when HSP110 is used as an adjuvant

  • Compare HSP110 to other heat shock proteins as immunomodulators

• In vivo immunization protocols:

  • Design HSP110-peptide complex isolation procedures

  • Develop immunization strategies with HSP110-peptide complexes

  • Monitor immune responses using techniques ranging from ELISpot to flow cytometry

These approaches can help elucidate HSP110's immunomodulatory mechanisms and optimize its use in vaccine development strategies.

How can advanced imaging techniques be combined with HSP110 antibodies for mechanistic studies?

Integrating HSP110 antibodies with cutting-edge imaging techniques provides powerful insights into chaperone function:

• Super-resolution microscopy:

  • Track individual HSP110 molecules using antibody-based labeling strategies

  • Examine nanoscale organization of HSP110 in chaperone complexes

  • Study co-localization with HSP70 and substrates at resolutions below the diffraction limit

• Live-cell imaging approaches:

  • Use cell-permeable fluorescently-labeled antibody fragments to track HSP110 dynamics

  • Employ FRAP (Fluorescence Recovery After Photobleaching) to study HSP110 mobility

  • Implement FRET (Förster Resonance Energy Transfer) to detect HSP110 interactions with partners

• Correlative light and electron microscopy (CLEM):

  • Localize HSP110 via immunofluorescence, then examine ultrastructural context

  • Study HSP110 association with aggregate structures at nano-resolution

  • Examine HSP110 localization relative to cellular organelles

• In vivo imaging applications:

  • Use near-infrared labeled antibodies for deeper tissue imaging

  • Track HSP110 expression in animal models of disease

  • Monitor therapeutic responses targeting the HSP110 pathway

These advanced imaging approaches, when combined with appropriate HSP110 antibodies, can reveal dynamic aspects of chaperone function not accessible through traditional biochemical methods.

How should researchers interpret variations in HSP110 detection across different experimental systems?

Interpreting HSP110 antibody data requires consideration of several factors that influence detection:

• Expression level variations:

  • Tissue-specific differences: HSP110 is most highly expressed in brain tissue

  • Stress-induced upregulation: Heat shock and other stressors can dramatically increase HSP110 levels

  • Developmental regulation: HSP110 expression may vary with developmental stage

• Technical considerations:

  • Antibody sensitivity differences between applications (WB vs. IHC vs. IF)

  • Sample preparation effects on epitope accessibility

  • Detection method sensitivity (chemiluminescence vs. fluorescence)

• Experimental context analysis:

  • Compare results to established positive controls

  • Consider relative rather than absolute expression differences

  • Track temporal changes rather than single timepoint measurements

• Reconciling contradictory findings:

  • Examine differences in experimental models (cell lines, animal models)

  • Consider genetic background effects on HSP110 function

  • Evaluate tissue-specific vs. organism-wide effects

When interpreting HSP110 detection data, researchers should be particularly attentive to the context of protein homeostasis, as HSP110 function is highly interconnected with other chaperone systems.

What controls are essential when using HSP110 antibodies in protein disaggregation studies?

Robust controls are critical when studying HSP110's role in protein disaggregation:

• Positive technical controls:

  • Known HSP110-expressing tissues/cells (brain tissue samples)

  • Recombinant HSP110 protein standards

  • Heat-shocked samples with induced HSP110 expression

• Negative technical controls:

  • HSP110 knockdown/knockout samples

  • Secondary antibody-only controls

  • Peptide competition controls to verify specificity

• Functional controls for disaggregation studies:

  • HSP70 inhibition/knockdown (expected to impair disaggregation)

  • ATP depletion (should inhibit chaperone function)

  • Use of model substrates with known disaggregation properties (e.g., FLUCSM::EGFP)

• System-specific controls:

  • For tissue-specific studies: Verify tissue-specific knockdown efficacy (e.g., using GFP-tagged HSP110)

  • For temporal studies: Include multiple timepoints to capture disaggregation dynamics

  • For protein specificity: Compare multiple substrate proteins to identify substrate-specific effects

These controls help distinguish HSP110-specific effects from general perturbations of protein homeostasis or technical artifacts.